Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors

BACKGROUND. This phase I study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics of pilaralisib (SAR245408), an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in combination with erlotinib, an epidermal growth factor receptor (EGFR) inhibit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Soria, Jean-Charles, LoRusso, Patricia, Bahleda, Ratislav, Lager, Joanne, Liu, Li, Jiang, Jason, Martini, Jean-François, Macé, Sandrine, Burris, Howard
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4350809/
https://ncbi.nlm.nih.gov/pubmed/25669662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados